- Home
- NMRK vs BLTE Comparison
NMRK vs BLTE Comparison
Compare NMRK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- BLTE
- Stock Information
- Founded
- NMRK 1929
- BLTE 2018
- Country
- NMRK United States
- BLTE United States
- Employees
- NMRK N/A
- BLTE N/A
- Industry
- NMRK Real Estate
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- BLTE Health Care
- Exchange
- NMRK Nasdaq
- BLTE Nasdaq
- Market Cap
- NMRK 2.0B
- BLTE 2.1B
- IPO Year
- NMRK 2017
- BLTE 2022
- Fundamental
- Price
- NMRK $11.01
- BLTE $64.87
- Analyst Decision
- NMRK Strong Buy
- BLTE Strong Buy
- Analyst Count
- NMRK 4
- BLTE 4
- Target Price
- NMRK $15.67
- BLTE $96.67
- AVG Volume (30 Days)
- NMRK 1.1M
- BLTE 30.4K
- Earning Date
- NMRK 04-30-2025
- BLTE 05-13-2025
- Dividend Yield
- NMRK 1.09%
- BLTE N/A
- EPS Growth
- NMRK 81.01
- BLTE N/A
- EPS
- NMRK 0.38
- BLTE N/A
- Revenue
- NMRK $2,857,497,000.00
- BLTE N/A
- Revenue This Year
- NMRK $13.16
- BLTE N/A
- Revenue Next Year
- NMRK $9.16
- BLTE N/A
- P/E Ratio
- NMRK $29.12
- BLTE N/A
- Revenue Growth
- NMRK 14.48
- BLTE N/A
- 52 Week Low
- NMRK $9.64
- BLTE $43.70
- 52 Week High
- NMRK $16.10
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- NMRK 47.90
- BLTE 55.26
- Support Level
- NMRK $10.20
- BLTE $60.23
- Resistance Level
- NMRK $12.13
- BLTE $66.10
- Average True Range (ATR)
- NMRK 0.37
- BLTE 2.80
- MACD
- NMRK -0.02
- BLTE 0.02
- Stochastic Oscillator
- NMRK 41.97
- BLTE 34.37
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.